If you or a loved one developed cutaneous T-cell lymphoma (CTCL) after using Dupixent, you’re not alone. Patients across the U.S. are filing Dupixent lawsuits alleging that the drug’s manufacturers failed to warn about a potential link between Dupixent and this rare but aggressive form of skin cancer.
In this video, the Oberheiden Law Group explains the key facts behind the Dupixent cancer lawsuit, what CTCL means for patients, and the first steps you can take to protect your legal rights.
💡 What You’ll Learn:
The truth about the Dupixent CTCL lawsuit
Why patients are filing legal claims
How Dupixent may be linked to cutaneous T-cell lymphoma
What to do if you’ve been diagnosed after using Dupixent
📞 Need Legal Help?
If you’ve been affected, speak with an experienced attorney today to learn your options. The first step is understanding your rights.
👉 Read More:
https://natlawreview.com/article/dupixent-lawsuit-10-key-facts-ctcl-patients-and-their-families
